Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwc who wrote (16306)	3/3/1998 11:42:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

dwc, The 30% refers to human breast cancers that are over-expressing HER2/neu. Only a subset of this subset respond to the antibody treatment. The response rate of breast cancer patients to Targretin is not known. Close to 90% of the rats with chemically induced breast cancer responded to Targretin.

To: dwc who wrote (16306)	3/3/1998 12:03:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's the initial abstract on neu: Nature 1984 Dec 6;312(5994):513-516 The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA A series of rat neuro/glioblastomas all contain the same transforming gene (neu) which induces synthesis of a tumour antigen of relative molecular mass (Mr) 185,000 (p185). The neu oncogene bears homology to erb-B and the tumour antigen, p185, is serologically related to the epidermal growth factor (EGF) receptor. The two proteins, EGF receptor and p185 appear to be distinct, as they coexist in nontransformed Rat-1 cells. PMID: 6095109, UI: 85061595